Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam

✍ Scribed by C. Benveniste; R. Striberni; P. Dayer

• Publisher: Springer
• Year: 1990
• Tongue: English
• Weight: 282 KB
• Volume: 38
• Category: Article
• ISSN: 0031-6970
• DOI: 10.1007/bf00278579

✦ Synopsis

To assess the extent of enterohepatic recycling of piroxicam and tenoxicam, their pharmacokinetics have been compared in the absence and presence of concomitant treatment with cholestyramine. In a randomized crossover study 6 healthy volunteers received piroxicam and tenoxicam 20 mg p.o., alone or with cholestyramine 24 g/day for 4 days. Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively). It also increased the apparent clearance (Cl/f) of piroxicam and tenoxicam by 58% and 112%. When cholestyramine was administered, the t 1/2 of piroxicam & tenoxicam were correlated (r = 0.89), which suggests that their hepatic biotransformation is under a common control. It is concluded that: piroxicam and tenoxicam are eliminated to a large and comparable extent through the biliary route, and the administration of cholestyramine may help to accelerate their elimination in cases of overdosage.